Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J plans to invest more than $55 billion in US over next four years
06:08am, Friday, 21'st Mar 2025
Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build manufacturing facilities and research infrastructure in the United States.
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
06:00am, Friday, 21'st Mar 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, announced manufacturing, research and de
Historic Dividend Outperformance
08:05pm, Thursday, 20'th Mar 2025
For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025. One of the most well-kn
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA®
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
04:15pm, Thursday, 20'th Mar 2025
PARIS and CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparti
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
01:55pm, Thursday, 20'th Mar 2025
Johnson & Johnson JNJ just hit a Golden Cross , a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple m
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regi
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
12:00pm, Wednesday, 19'th Mar 2025
The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study T
Got $300? Buy These 3 Top Dividend Stocks and Never Look Back.
04:34am, Tuesday, 18'th Mar 2025
Some companies are just better than others at paying dividends. They offer higher-yielding payouts that they steadily increase in good times and bad.
Resilient Investing: 3 Stocks Built to Weather Market Volatility
08:46am, Monday, 17'th Mar 2025
As inflationary pressures persist and the specter of a potential recession looms, investors are understandably seeking stability. While predicting market movements is always challenging, focusing on c
The S&P 500 Is in Correction Territory: 4 Surefire Stocks to Buy Right Now
04:41am, Monday, 17'th Mar 2025
It's official! As of the closing bell on March 13, the benchmark S&P 500 (^GSPC 2.13%), which is comprised of 500 of the most-influential businesses traded on U.S. stock exchanges, had entered correct
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
01:40pm, Sunday, 16'th Mar 2025
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and
An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.
05:07am, Saturday, 15'th Mar 2025
Johnson & Johnson executives are scheduled to take the stand in a trial starting Monday. ChemImage, a small biotech firm, sued the healthcare giant over a 2019 partnership that went south.
Johnson & Johnson (JNJ) Could Be a Great Choice
12:45pm, Friday, 14'th Mar 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
